HPV and Pap Testing Market Growth Accelerates With Diagnostic Innovation

HPV Testing and Pap Test Market Advances With Screening Expansion

The HPV and Pap testing market is experiencing consistent growth as healthcare systems increasingly prioritize cervical cancer prevention, early detection, and accessible screening. HPV testing helps identify high-risk human papillomavirus infections linked to cervical cancer, while Pap testing detects abnormal cervical cell changes that may indicate precancerous lesions. According to DelveInsight, the global market was valued at approximately USD 3,702.30 million in 2025 and is expected to reach USD 6,524.39 million by 2034, reflecting a CAGR of 6.56% during 2026–2034.

HPV Testing and Pap Test Market Benefits From Rising Cervical Cancer Burden

The growing incidence of cervical cancer is creating sustained demand within the HPV testing and Pap test market. Persistent infection with high-risk HPV strains is recognized as the primary cause of cervical cancer, while infections can remain undetected for extended periods. Regular screening therefore plays a critical role in identifying HPV infections and abnormal cellular changes before they develop into invasive disease.

Data referenced by DelveInsight from the International Agency for Research on Cancer indicate that approximately 702,616 new cervical cancer cases were estimated in 2025. This figure could rise to 908,612 cases by 2045. The projected increase is encouraging governments, healthcare organizations, and diagnostic companies to strengthen screening infrastructure and improve early detection capabilities.

HPV Testing Pap Test Market Gains From Molecular Diagnostic Innovation

Technological development is transforming the HPV testing Pap test market through improvements in diagnostic accuracy, automation, sensitivity, and testing efficiency. Molecular technologies, including polymerase chain reaction-based assays and mRNA testing, allow laboratories to identify high-risk HPV infections with greater efficiency compared with cytology-based approaches alone.

Molecular diagnostics are anticipated to remain a leading technology segment, representing around 43% of the market in 2025. Greater use of primary HPV screening, automated laboratory systems, and high-throughput testing platforms is expected to create further opportunities for diagnostic manufacturers.

Recent regulatory developments also demonstrate continued innovation. In February 2026, Hologic received FDA approval for its Aptima HPV Assay for clinician-collected HPV primary screening, highlighting the expanding role of molecular diagnostics in contemporary cervical cancer screening.

HPV Testing Market Maintains Strong Demand for Pap-Based Screening

Although HPV-based screening continues to gain momentum, Pap testing remains an established element of cervical cancer prevention. The HPV testing market continues to benefit from the complementary use of cytology for follow-up evaluation and co-testing approaches.

Pap testing represented approximately 63% of total market revenue in 2025. Its established clinical acceptance, affordability, and integration into long-standing screening programs continue to support demand. Liquid-based cytology has further improved specimen quality and laboratory workflows, helping sustain adoption across both developed and emerging healthcare systems.